IRulya Therapeutics Inc. IRLA
Set alert
32.95 USD +1.33 +4.21%
At close · Oct 30
32.95 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
30.00 Day range 34.26
16.00 52-week range 880.00
- YTD
- -95.08%
- 1 year
- -90.02%
- Open
- 30.67
- Prev close
- 31.62
- Mkt cap
- 33.51M
- Vol
- 98.00K
- Avg vol
- 42.42K
- EPS
- -214.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 30.00
- High
- 34.26
6M chart
Signals (19)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 29, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
Financials — quick view
IRLA Revenue — quarterly 0
IRLA Net income — quarterly -75.49M
IRLA EPS — quarterly -12.31
News
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
- Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker
- Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
- Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans
- Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
- Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
- Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
- Quince Therapeutics to Participate in September 2026 Investor Conferences
- Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Your note
Sign in to keep a note on IRLA — it syncs with the Stock Master app.